Population pharmacokinetic analyses for BC-3781 using phase 2 data from patients with acute bacterial skin and skin structure infections

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 282-288

  Rubino, C M ^a   Xue, B ^a,c   Bhavnani, S M ^a   Prince, W T ^b   Ivezic Schoenfeld, Z ^b   Wicha, W W ^b   Ambrose, P G ^a  

^a INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^b Nabriva Therapeutics Inc   (Austria)

^c FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BC 3781; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; BC-3781; DITERPENE; THIOGLYCOLIC ACID DERIVATIVE;

ACCURACY; ADULT; ARTICLE; BACTERIAL SKIN DISEASE; BODY SIZE; COMPARTMENT MODEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; FEMALE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MONTE CARLO METHOD; PHASE 2 CLINICAL TRIAL; SKIN STRUCTURE; VOLUME OF DISTRIBUTION; ADOLESCENT; AGE; AGED; BIOLOGICAL MODEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; KIDNEY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASES, BACTERIAL; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTI-BACTERIAL AGENTS; BODY SIZE; DITERPENES; FEMALE; HUMANS; KIDNEY; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MONTE CARLO METHOD; SKIN DISEASES, BACTERIAL; THIOGLYCOLATES; YOUNG ADULT;

EID: 84920179009     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02033-13     Document Type: Article

References (13)

1. Sader HS, Biedenbach DJ, Paukner S, Ivezic-Schoenfeld Z, Jones RN. 2012. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against Gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 56:1619-1623. http://dx.doi.org/10.1128/AAC.05789-11.
2. Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. 2012. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother 67:1170-1175. http://dx.doi.org/10.1093/jac/dks001.
3. th Intersci Conf Antimicrob Agents Chemother.
4. Gehan EA, George SL. 1970. Estimation of human body surface area from height and weight. Cancer Chemother Rep 54:225-235.
5. Cockcroft DW, Gault MH. 1976. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41. http://dx.doi.org/10.1159/000180580.
6. Food and Drug Administration. 2001. Guidance for industry: bioanalytical method validation. Department of Health and Human Services, Washington, DC.
7. Anonymous. 1999. Guidance for industry on population pharmacokinetics; availability. Food and Drug Administration, HHS. Notice Fed Regist 64:6663-6664.
8. Beal SL. 2001. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28:481-504. http://dx.doi .org/10.1023/A:1012299115260.
9. Bauer RJ. 2006. S-ADAPT/MCPEM. User's guide: software for pharmacokinetic, pharmacodynamic, and population data analysis. Robert J. Bauer, Berkeley, CA. http://bmsr.usc.edu/downloads/s-adapt.
10. D'Argenio DZ, Schumitzky A. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Comput Programs Biomed 9:115-134. http://dx.doi.org/10.1016/0010-468X(79)90025-4.
11. D'Argenio DZ, Schumitzky A. 2003. ADAPT II user's guide: pharmacokinetic/ pharmacodynamic systems analysis software. BMSR Biomedical Simulations Resource, Los Angeles, CA.
12. Akaike H. 1979. Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237-242. http://dx.doi.org/10 .1093/biomet/66.2.237.
13. st Intersci Conf Antimicrob Agents Chemother.